InSolution Casein Kinase II Inhibitor I

Analysis Note

Single spot by TLC

Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Target IC₅₀: 900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively

Primary TargetCK2 rat liver, human recombinant

Cell permeable: yes

General description

A cell-permeable, highly selective, ATP/GTP-competitive casein kinase II (CKII) inhibitor (IC₅₀ = 900 nM and 1.6 µM for rat liver and human recombinant CKII, respectively) and DYRK (IC₅₀﹤1 µM for DYRK1a). Specificity for CKII has been reported following the screening of 33 kinases, including PKA, Akt, PKC, MKK1, ERK2, p38, JNK, Lck, Lyn, and Syk. Also reported to inhibit NS3-associated viral helicase activity in hepatitis C virus (HCV) (IC₅₀ = 20 and 60 µM using DNA and RNA substrates, respectively) and West Nile virus (WNV) (IC₅₀ = 1.7 µM and 900 nM using DNA and RNA substrates, respectively).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Borowski, P., et al. 2003. Eur. J. Biochem.270, 1645.Zien, P., et al. 2003. Biochem. Biophys. Res. Commun.306, 129.Sarno, S., et al. 2003. Biochem. J.374, 639.Sarno, S., et al. 2001. FEBS Lett.496, 44.Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun.208, 418."

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Physical form

A 10 mM (5 mg/1.15 ml) solution of Casein Kinase II Inhibitor I (Cat. No. 218697) in DMSO.

Reconstitution

Following initial use, aliquot and refrigerate (4°C).

Warning

Toxicity: Carcinogenic / Teratogenic (D)